论文部分内容阅读
目的:通过观察急性冠脉综合征(ACS)伴有不同程度慢性肾脏病(CKD)患者血浆P选择素水平,探讨血浆P选择素在ACS合并CKD中的意义。方法:选择ACS患者90例,其中单纯ACS患者32例,ACS合并轻度CKD患者35例,ACS合并中重度CKD患者23例,正常对照28例。所有病例采用ELISA法测定血浆可溶性P选择素水平。结果:单纯ACS和ACS合并不同程度CKD患者的血浆P选择素水平均显著高于正常对照组,而ACS合并CKD组血浆P选择素水平高于单纯ACS组(P<0.05),ACS合并轻度CKD患者血浆P选择素高于ACS合并中重度CKD患者(P<0.05)。结论:血浆P选择素参与CKD的发生发展过程,可作为ACS早期肾损害的重要检测指标。
Objective: To investigate the significance of plasma P-selectin in ACS with CKD by observing the plasma P-selectin level in patients with acute coronary syndrome (ACS) accompanied with varying degrees of chronic kidney disease (CKD). Methods: Ninety ACS patients were selected, including 32 patients with ACS, 35 patients with ACS with mild CKD, 23 patients with moderate-severe CKD and 28 patients with normal CK. Plasma soluble P-selectin levels were measured by ELISA in all cases. Results: Plasma P-selectin levels were significantly higher in ACS patients with CKD alone and in ACS patients with CKD than those in ACS patients (P <0.05) Plasma P-selectin in CKD patients was higher than that in ACS patients with moderate-severe CKD (P <0.05). Conclusion: Plasma P-selectin is involved in the development and progression of CKD, which can be used as an important detection index of early renal damage in ACS.